Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 12/20 | 1.00 |
| ▸ | KLK1 | P06870 | 11/20 | 1.00 |
| ▸ | KLK6 | Q92876 | 10/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 1/20 | 0.65 |
| ▸ | PLAU | P00749 | 1/20 | 0.65 |
| ▸ | PLAT | P00750 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22799450 | 0.99 | PLG (1.00) | PLGKLK1KLK6KLKB1ALOX15 | |
| SCHEMBL29376081 | 0.83 | PLG (0.71) | PLGKLK1KLK6KLKB1ALOX15 | |
| SCHEMBL9826365 | 0.82 | ALOX15 (1.00) | PLGKLK1KLK6KLKB1ALOX15 | |
| SCHEMBL22799056 | 0.82 | PLG (1.00) | PLGKLK1KLK6KLKB1 | |
| Hydrochloric Acid SCHEMBL22799447 | 0.81 | PLG (1.00) | PLGKLK1KLK6KLKB1 | |
| SCHEMBL14514566 | 0.80 | PLG (0.67) | PLGKLK1KLK6ALOX15F2 | |
| SCHEMBL18285117 | 0.79 | KLKB1 (0.73) | PLGKLK1KLK6KLKB1 | |
| SCHEMBL24891739 | 0.78 | PLG (0.64) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL11594657 | 0.78 | NPC1 (0.66) | PLGKLK1KLK6KLKB1ALOX15 | |
| SCHEMBL30182163 | 0.78 | PLG (0.64) | PLGKLK1KLK6KLKB1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541023-B2 | Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases | SARBONNE UNIVERSITE (FR) | 2023-01-03 | — | — | US | claimed |
| EP-3752138-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIV SORBONNE (FR) | 2022-02-09 | — | — | EP | claimed |
| US-20210046026-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2021-02-18 | — | — | US | claimed |
| EP-3752138-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2020-12-23 | — | — | EP | claimed |
| WO-2019158859-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2019-08-22 | — | — | WO | claimed |
| US-11541023-B2 | Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases | SARBONNE UNIVERSITE (FR) | 2023-01-03 | — | — | US | disclosed |
| EP-3752138-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIV SORBONNE (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210046026-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2021-02-18 | — | — | US | disclosed |
| EP-3752138-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019158859-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541023-B2 | Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases | KLKB1, KLK5, KLK1 | PLG 53/4885KLK1 3/4885KLK6 8/4885 |
| US-20210046026-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | KLKB1, KLK5, KLK1 | PLG 53/4885KLK1 3/4885KLK6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.